Identify patients for CABENUVA in your practice
“I was always concerned that somebody would find my pills and discover that I was HIV positive.”
Steve — Patient Ambassador
See Steve’s HIV treatment story
CABENUVA access and affordability
Get comprehensive support from benefit verification to reimbursement to acquisition to co-pay collection.
Questions to ask your patients about taking daily oral therapy
Reference:
- Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577. doi.org/10.1016/S2352-3018(23)00136-4
CBRWCNT230015